ArticleExperimental and therapeutic medicine2017
Evaluation of the effect of recombinant thrombomodulin on a lipopolysaccharide-induced murine sepsis model.
Article in Experimental and therapeutic medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 29 citations in OpenAlex.
- Pharmacological intervention of the HMGB1-pCTS-L axis to ameliorate inflammatory diseases.Frontiers in immunology · 2026Review
- Soluble Thrombomodulin as a Marker of Endothelial Injury in Early Post-Transplant Period: A Comparative Study of Simple Hypothermia and Pulsatile Machine Perfusion in Kidney Graft Preservation.Journal of clinical medicine · 2025Article
- Thrombomodulin: A key regulator of intravascular blood coagulation, fibrinolysis, and inflammation, and a treatment for disseminated intravascular coagulation.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2025Review
- Article
- Absence of the lectin-like domain of thrombomodulin reduces HSV-1 lethality of mice with increased microglia responses.Journal of neuroinflammation · 2022Article
- Review
- Association between thrombomodulin and high mobility group box 1 in sepsis patients.World journal of critical care medicine · 2020Article
- Article
- Recombinant human thrombomodulin attenuated sepsis severity in a non-surgical preterm mouse model.Scientific reports · 2020Article
- Thrombomodulin as a Physiological Modulator of Intravascular Injury.Frontiers in immunology · 2020Review
- Time to Develop Therapeutic Antibodies Against Harmless Proteins Colluding with Sepsis Mediators?ImmunoTargets and therapy · 2020Review
- The Protective Effects of Melatonin Against LPS-Induced Septic Myocardial Injury: A Potential Role of AMPK-Mediated Autophagy.Frontiers in endocrinology · 2020Article
- Guiding Effect of Serum Procalcitonin (PCT) on the Antibiotic Application to Patients with Sepsis.Iranian journal of public health · 2017Article
- A two-decade journey in identifying high mobility group box 1 (HMGB1) and procathepsin L (pCTS-L) as potential therapeutic targets for sepsis.Expert opinion on therapeutic targetsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the effect of recombinant human thrombomodulin (rTM) on sepsis, the levels of nucleosome as well as high-mobility group box 1 (HMGB1) and cytokines in sera and peritoneal fluids were measured in a mouse model of lipopolysaccharide (LPS)-induced sepsis after administration of rTM. C57BL/6 mice were intraperitoneally injected with LPS (15 mg/kg;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.